U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Vaccines, Blood & Biologics
  3. International Activities
  4. Foreign Regulatory Seminar (Web-Based) - Office of Compliance and Biologics Quality
  1. International Activities

Foreign Regulatory Seminar (Web-Based) - Office of Compliance and Biologics Quality

Compliance and Product Quality

Detailed discussion on regulatory actions, recalls and product deviation reports associated with inspections.


Inspections of CBER Regulated Products

Overview discussion on types of inspections, inspection teams, scope and coverage, and outcomes of an inspection.


CBER’s Bioresearch Monitoring Program: Clinical and Nonclinical Inspections

Overview of the Bioresearch Monitoring (BIMO) program at CBER, covering Good Clinical Practice and Good Laboratory Practice compliance as it relates to human subject protection, clinical trial data, and inspections.


Division of Biological Standards and Product Quality (DBSQC)

Discussion of the activities within the Division of Biological Standards and Product Quality and its testing laboratories, as part of the Office of Compliance and Biologics Quality. Discussion includes quality systems, product testing, lot release, reference reagents and physical standards, and method validation.


CBER’s Lot Release System: Overview of the Current Process

Detailed discussion of the receipt, processing and release of product lots via the lot release system, within the Division of Manufacturing and Product Quality, which includes review and testing.


Return to Foreign Regulatory Seminar (Web-Based)

Back to Top